ClinicalTrials.gg
CompletedNCT07141199Updated Apr 28, 2026

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

A Phase 1 interventional study of ABBV-8736 and Placebo in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-8736
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) is >= 18.0 to \<= 32.0 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • Prior exposure to a TREM1 agent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1: Dose A of ABBV-8736

    Participants will receive intravenous (IV) ABBV-8736 dose A every 2 weeks for a total of 3 doses.

    Drug: ABBV-8736

  • Placebo comparator
    Group 1: Dose A of ABBV-8736 Placebo

    Participants will receive IV ABBV-8736 placebo dose A every 2 weeks for a total of 3 doses.

    Drug: Placebo

  • Experimental
    Group 2: Dose B of ABBV-8736

    Participants will receive IV ABBV-8736 dose B every 2 weeks for a total of 3 doses.

    Drug: ABBV-8736

  • Placebo comparator
    Group 2: Dose B of ABBV-8736 Placebo

    Participants will receive IV ABBV-8736 placebo dose B every 2 weeks for a total of 3 doses.

    Drug: Placebo

Interventions

  • Intravenous (IV) Infusion

  • DrugPlacebo

    IV Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 113 Days

  2. Maximum Observed Concentration (Cmax) of ABBV-8736

    Cmax of ABBV-8736.

    Time frame: Up to Approximately 113 Days

  3. Time to Cmax (Tmax) of ABBV-8736

    Tmax of ABBV-8736.

    Time frame: Up to Approximately 113 Days

  4. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of ABBV-8736

    AUCtau of ABBV-8736.

    Time frame: Up to Approximately 113 Days

  5. Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-8736

    Ctrough of ABBV-8736.

    Time frame: Up to Approximately 113 Days

  6. Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-8736

    β of ABBV-8736.

    Time frame: Up to Approximately 113 Days

  7. Terminal Phase Elimination Half-Life (t1/2) of ABBV-8736

    t1/2 of ABBV-8736.

    Time frame: Up to Approximately 113 Days

  8. Clearance (CL) for Intravenous (IV) Dosing

    CL for IV dosing.

    Time frame: Up to Approximately 113 Days

  9. Immunogenicity of ABBV-8736 as Determined by Anti-Drug Antibodies (ADAs)

    Incidence and concentrations of ADAs. Neutralizing ADAs (NAb) may be evaluated.

    Time frame: Up to Approximately 113 Days

07

Study locations

1 site
  • Acpru /Id# 277377
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Mar 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 26, 2025
StartActual
Sep 2, 2025
Primary completionActual
Mar 23, 2026
CompletionActual
Mar 23, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07141199
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Sep 2, 2025
Primary completion
Mar 23, 2026
Completion
Mar 23, 2026
Last update
Apr 28, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-8736

Start the discussion